Flanvotumab
Flanvotumab, also known as IMC-20D7S, is a human monoclonal antibody designed for the treatment of melanoma. It targets TYRP1. Flanvotumab was developed by ImClone Systems, now owned by Eli Lilly.
Link from a Wikipage to another Wikipage
primaryTopic
Flanvotumab
Flanvotumab, also known as IMC-20D7S, is a human monoclonal antibody designed for the treatment of melanoma. It targets TYRP1. Flanvotumab was developed by ImClone Systems, now owned by Eli Lilly.
has abstract
Flanvotumab, also known as IMC ...... stems, now owned by Eli Lilly.
@en
فلانفوتوماب هو جسم مضاد وحيد النسيلة بشري مصمم لعلاج الميلانوما.
@ar
CAS number
1188277-05-5
FDA UNII code
ZNV4738BS6
Wikipage page ID
33,024,003
page length (characters) of wiki page
Wikipage revision ID
963,846,711
Link from a Wikipage to another Wikipage
ATC prefix
none
@en
CAS number
ChemSpiderID
none
@en
mab type
mab
@en
source
u
@en
target
type
mab
@en
UNII
ZNV4738BS6
@en
Verifiedfields
changed
@en
verifiedrevid
457,119,901
Watchedfields
changed
@en
wikiPageUsesTemplate
hypernym
comment
Flanvotumab, also known as IMC ...... stems, now owned by Eli Lilly.
@en
فلانفوتوماب هو جسم مضاد وحيد النسيلة بشري مصمم لعلاج الميلانوما.
@ar
label
Flanvotumab
@en
فلانفوتوماب
@ar